ERBB2 and neoplasm: Among patients with HR+, HER2- node positive EBC, 15,083 (25.7%) met the monarchE criterion of ≥4 positive ALNs and 13,536 (23.1%) met the criteria of 1–3 positive ALNs in combination with either a primary invasive tumor size ≥5 cm or histological Grade 3 tumor (S1 Fig).